Euroopa Liit - eesti - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastilised ained - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lümfoom, mantle-cell - antineoplastilised ained - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Eesti - eesti - Adama

adama - suspensioonikontsentraat - asoksüstrobiin + tsüprokonasool - fungitsiidid

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mitu müeloomit - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - mitu müeloomit - antineoplastilised ained - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Eesti - eesti - Ravimiamet

mepha-investigacao, desenvolvimento e fabricacao farmaceutica, lda - asitromütsiin - õhukese polümeerikattega tablett - 500mg 2tk; 500mg 30tk; 500mg 6tk; 500mg 150tk

Eesti - eesti - Ravimiamet

mepha-investigacao, desenvolvimento e fabricacao farmaceutica, lda - asitromütsiin - õhukese polümeerikattega tablett - 250mg 4tk; 250mg 6tk; 250mg 3tk; 250mg 100tk

Eesti - eesti - Ravimiamet

teva b.v. - imipeneem+tsilastatiin - infusioonilahuse pulber - 500mg+500mg 1tk; 500mg+500mg 10tk

Eesti - eesti - Ravimiamet

eugia pharma (malta) limited - piperatsilliin+tasobaktaam - infusioonilahuse pulber - 4000mg+500mg 1tk; 4000mg+500mg 12tk

Eesti - eesti - Ravimiamet

vetoquinol biowet sp. z o.o. - tiamuliin - suukaudse lahuse graanulid - 450mg 1g 1000g 1tk